A carregar...
Initial apixaban dosing in patients with atrial fibrillation
BACKGROUND: Apixaban is a non–vitamin K oral anticoagulant approved for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). Current labeling recommends dose reduction based on patient age, weight, and renal function. HYPOTHESIS: The aim of this study was...
Na minha lista:
| Publicado no: | Clin Cardiol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wiley Periodicals, Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6489803/ https://ncbi.nlm.nih.gov/pubmed/29542830 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22949 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|